Cancer outcomes and all-cause mortality in adults allocated to metformin: systematic review and collaborative meta-analysis of randomised clinical trials
AIMS/HYPOTHESIS: Observational studies suggest that metformin may reduce cancer risk by approximately one-third. We examined cancer outcomes and all-cause mortality in published randomised controlled trials (RCTs). METHODS: RCTs comparing metformin with active glucose-lowering therapy or placebo/usu...
Main Authors: | Stevens, R, Ali, R, Bankhead, C, Holman, R, al., E |
---|---|
Format: | Journal article |
Language: | English |
Published: |
Springer
2012
|
Similar Items
-
Cancer outcomes and all-cause mortality in adults allocated to metformin: Systematic review and collaborative meta-analysis of randomised clinical trials
by: Stevens, R, et al.
Published: (2012) -
Cancer outcomes and all-cause mortality in adults allocated to metformin: systematic review and collaborative meta-analysis of randomised clinical trials.
by: Stevens, R, et al.
Published: (2012) -
Erratum to: Cancer outcomes and all-cause mortality in adults allocated to metformin: systematic review and collaborative meta-analysis of randomised clinical trials.
by: Stevens, R, et al.
Published: (2012) -
Erratum: Cancer outcomes and all-cause mortality in adults allocated to metformin: Systematic review and collaborative meta-analysis of randomised clinical trials (Diabetologia DOI: 10.1007/s00125-012-2653-7)
by: Stevens, R, et al.
Published: (2012) -
Metformin and mortality. Reply to Lund SS [letter]
by: Stevens, R, et al.
Published: (2013)